Status:
COMPLETED
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Lead Sponsor:
Basilea Pharmaceutica
Conditions:
Hand Dermatoses
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to furth...
Eligibility Criteria
Inclusion
- Previous participation in protocol BAP089
- Response of severe, treatment refractory hand dermatitis with mild or moderate, or responding patients who relapsed to 75% of baseline disease
Exclusion
- Female patients who are pregnant or who want to become pregnant
- Female patients of child bearing potential who cannot use or who will not commit to using two effective methods of contraception
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00124436
Start Date
March 1 2005
End Date
February 1 2007
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Ruzicka
Düsseldorf, Germany, 40225